荷兰成人社区获得性肺炎窄谱抗生素管理干预试验(CAP-PACT)
在荷兰12家医院开展的前瞻性、阶梯整群随机、非劣效性试验,纳入4084例非ICU住院的中重度社区获得性肺炎成人患者。
要点
- 多模式抗菌药物管理干预可安全减少中重度CAP住院患者的广谱抗生素使用。
- 90天死亡率干预前后无显著差异,符合预设的非劣效界值3%。
核心结论
- 在非ICU住院的中重度社区获得性肺炎成人中,多模式抗菌药物管理干预可能安全地减少广谱抗生素使用。
研究设计与样本
- 横断面、阶梯整群随机、非劣效性抗菌药物管理干预试验(CAP-PACT),在荷兰12家医院开展。
- 纳入免疫正常、年龄≥18岁、非ICU病房住院、工作诊断为中重度社区获得性肺炎的成人。
- 所有医院从对照期开始,每3个月有两个医院从对照期转为干预期,最终全部进入干预期。
- 随机化单位为医院(整群),由独立数据管理员通过电子随机化决定医院交叉顺序,无法设盲。
- 意向性治疗分析共纳入4084例患者(对照期2235例,干预期1849例)。
关键数值与推荐
- 共主要结局:广谱抗生素人均治疗天数采用优效性检验;90天全因死亡率采用非劣效性检验,非劣效界值为3%。
- 抗菌药物管理干预为多模式组合,针对医务人员,包括教育、吸引意见领袖参与、以及抗生素使用的前瞻性审核与反馈。
临床怎么用
- 对于非ICU住院的中重度社区获得性肺炎成人,可实施包含教育、意见领袖参与和前瞻性审核反馈的多模式抗菌药物管理干预,以安全减少广谱抗生素使用。
局限性
- 研究无法设盲。
- 试验在荷兰开展,结论外推需考虑当地抗菌药物处方背景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adults hospitalised to a non-intensive care unit (ICU) ward with moderately severe community-acquired pneumonia are frequently treated with broad-spectrum antibiotics, despite Dutch guidelines recommending narrow-spectrum antibiotics. Therefore, we investigated whether an antibiotic stewardship intervention would reduce the use of broad-spectrum antibiotics in patients with moderately severe community-acquired pneumonia without compromising their safety. METHODS: In this cross-sectional, stepped-wedge, cluster-randomised, non-inferiority trial (CAP-PACT) done in 12 hospitals in the Netherlands, we enrolled immunocompetent adults (≥18 years) who were admitted to a non-ICU ward and had a working diagnosis of moderately severe community-acquired pneumonia. All participating hospitals started in a control period and every 3 months a block of two hospitals transitioned from the control to the intervention period, with all hospitals eventually ending in the intervention period. The unit of randomisation was the hospital (cluster), and electronic randomisation (by an independent data manager) decided the sequence (the time of intervention) by which hospitals would cross over from the control period to the intervention period. Blinding was not possible. The antimicrobial stewardship intervention was a bundle targeting health-care providers and comprised education, engaging opinion leaders, and prospective audit and feedback of antibiotic use. The co-primary outcomes were broad-spectrum days of therapy per patient, tested by superiority, and 90-day all-cause mortality, tested by non-inferiority with a non-inferiority margin of 3%, and were analysed in the intention-to-treat population, comprising all patients who were enrolled in the control and intervention periods. This trial was prospectively registered at ClinicalTrials.gov, NCT02604628. FINDINGS: Between Nov 1, 2015, and Nov 1, 2017, 5683 patients were assessed for eligibility, of whom 4084 (2235 in the control period and 1849 in the intervention period) were included in the intention-to-treat analysis. The adjusted mean broad-spectrum days of therapy per patient were reduced from 6·5 days in the control period to 4·8 days in the intervention period, yielding an absolute reduction of -1·7 days (95% CI -2·4 to -1·1) and a relative reduction of 26·6% (95% CI 18·0-35·3). Crude 90-day mortality was 10·9% (242 of 2228 died) in the control period and 10·8% (199 of 1841) in the intervention period, yielding an adjusted absolute risk difference of 0·4% (90% CI -2·7 to 2·4), indicating non-inferiority. INTERPRETATION: In patients hospitalised with moderately severe community-acquired pneumonia, a multifaceted antibiotic stewardship intervention might safely reduce broad-spectrum antibiotic use. FUNDING: None.
引用
- Schweitzer VA, van Heijl I, Boersma WG, et al. Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial. Lancet Infect Dis. 2021. PMID: 34627499. doi:10.1016/S1473-3099(21)00255-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。